Home
About
Team
Portfolio
News
FAQ
Contact

News

BioAdvance investments topped $3M in fiscal 2017

Aug 14, 2017

BioAdvance investments topped $3M in fiscal 2017

Comments are closed.

Current News

Opsidio Announces First Patient Dosed in Phase 2a Trial of OpSCF in Moderate to Severe Atopic Dermatitis
Palvella Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations
SIRPant Immunotherapeutics Receives FDA Orphan Drug Designation for SIRPant-M for the Treatment of T-Cell Lymphoma
Vittoria Biotherapeutics Secures Over $15 Million in Private Financing Round to Support the Development of Novel CAR-T Cell Therapies
VESTECK, Inc. “it is always someone’s mom or dad, brother or sister.”

© 2013-2023 BioAdvance. All rights reserved.